CTAD as a universal anticoagulant

Area of Science:

• Clinical Chemistry
• Hematology
• Medical Laboratory Science

Background:

• Anticoagulants are crucial for preserving blood sample integrity.
• Existing anticoagulants like EDTA and citrate have limitations.
• There is a need for novel anticoagulants in laboratory diagnostics.

Purpose of the Study:

• To evaluate the feasibility of CTAD (citrate, theophylline, adenosine, dipyridamole) as a new anticoagulant.
• To compare CTAD's performance against established anticoagulants (EDTA, citrate).
• To assess CTAD's impact on various laboratory test parameters.

Main Methods:

• Prospective study design.
• Whole blood samples were anticoagulated with CTAD.
• Comparison of complete blood counts, white cell differentials, plasma chemistry, and coagulation tests (PT, aPTT, fibrinogen) with EDTA and citrate anticoagulated samples.

Main Results:

• CTAD demonstrated high similarity to EDTA for complete blood count and white cell differential.
• Minor reductions in platelet count and mean platelet volume were observed with CTAD.
• Plasma chemistry results from CTAD were comparable to serum.
• Coagulation test results (PT, aPTT, fibrinogen) were similar to citrate plasma.

Conclusions:

• CTAD is a feasible and effective anticoagulant for medical laboratory applications.
• CTAD offers comparable performance to existing anticoagulants for a wide range of tests.
• CTAD presents a promising alternative anticoagulant for laboratory diagnostics.